Anemia - Pipeline Assessment and Market Forecasts to 2017 now available at SandlerResearch

GlobalData, the industry analysis specialist, has released its new report, "Anemia - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Anemia market. End Quote

(1888PressRelease) November 12, 2010 - Dallas, TX - SandlerResearch announce Anemia - Pipeline Assessment and Market Forecasts to 2017.

Browse complete Report at : http://www.sandlerresearch.org/reports/37162-anemia-pipeline-assessment-and-market-forecasts-to-2017.html

The report identifies the key trends shaping and driving the global Anemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in sales of the drugs. Since then, growth in the anemia market has been declining. Between 2009 and 2017, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Furthermore, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2017. This factor is also expected to restrain the growth of the market.

Scope
The report provides information on the key drivers and challenges of the Anemia market. Its scope includes:
Annualized global Anemia market revenues data from 2001 to 2009, forecast for eight years to 2017.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Erythropoesis Stimulating Agent, Oral HIF-PH inhibitor, TGF- beta inhibitors, Fetal globin gene expression stimulator, oral EPO inducers, EPO mimetic peptide.
Analysis of the current and future competition in the global Anemia market. Key market players covered are Amgen Inc, Roche, Jhonson & Jhonson, Vifor Inc, and Affymax.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anemia therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Anemia market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anemia market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What's the next big thing in the global Anemia market landscape? - Identify, understand and capitalize

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Anemia Market: Disease Overview 6
2.1 Overview 6
2.1.1 Macrocytic-normochromic anemia 6
2.1.2 Microcytic-hypochromic anemia 6
2.1.3 Normocytic-normochromic anemia 6
2.2 Signs and Symptoms 6
2.3 Severity of Anemia 7
2.4 Diagnosis 7
2.4.1 Physical Exam 7
2.4.2 Diagnostic Tests 7
2.5 Treatment 8
2.5.1 Dietary Changes and Supplements 8
2.5.2 Treatment with Medicines 8
2.5.3 Procedures 8
3 Anemia Market: Market Characterization 10
3.1 Overview 10
3.2 Anemia Market Size 10
3.3 Anemia Market Forecast and CAGR 12
3.4 Drivers and Barriers for the Anemia Market 13
3.4.1 Drivers for the Anemia Market 13
3.4.2 Restraints for the Anemia Market 13
3.5 Opportunity and Unmet Need 14
3.5.1 Impact Analysis of Unmet Needs 14
3.6 Key Takeaway 15
4 Anemia Market: Competitive Assessment 16
4.1 Overview 16
4.2 Strategic Competitor Assessment 16
4.3 Product Profile for the Major Marketed Products in the Anemia Market 17
4.3.1 Aranesp (darbepoetin alfa) 17
4.3.2 Procrit/Epogen/Eprex (epoetin alfa) 22
4.3.3 Venofer (iron sucrose injection, USP) 25
4.3.4 Mircera (methoxy polyethylene glycol-epoetin beta) 28
4.3.5 NeoRecormon (epoetin beta) 31
4.4 Key Takeaway 32
5 Anemia Market: Pipeline Assessment 34
5.1 Overview 34
5.2 Strategic Pipeline Assessment 34
5.2.1 Technology Trends Analytic Framework 34
5.3 Anemia - Promising Drugs under Clinical Development 36
5.4 Molecule Profile for Promising Drugs under Clinical Development 36
5.4.1 Hematide (peginesatide) 36
5.5 Anemia Market - Clinical Pipeline by Mechanism of Action 37
5.6 Anemia Pipeline - Pipeline by Clinical Phases of Development 38
5.6.1 Anemia - Regulatory Filing and Phase III Clinical Pipeline 38
5.6.2 Anemia - Phase II Clinical Pipeline 39
5.6.3 Anemia - Phase I Clinical Pipeline 39
5.6.4 Anemia - Preclinical Pipeline 40
5.7 Discontinued / Suspended Drugs for Anemia 40
5.8 Key Takeaway 40
6 Anemia Market: Implications for Future Market Competition 41
7 Anemia Market: Future Players in the Anemia Market 42
7.1 Introduction 42
7.2 Affymax 42
7.2.1 Company Overview 42
7.2.2 Financial Performance 43
7.2.3 Anemia Pipeline Drugs 43
7.3 Amgen Inc 43
7.3.1 Company Overview 43
7.3.2 Business Description 43
7.3.3 Anemia Pipeline Drugs 44
7.4 Chugai Pharmaceutical 44
7.4.1 Company Overview 44
7.4.2 Financial Performance 44
7.4.3 Business Description 44
7.4.4 Anemia Pipeline Drugs 45
7.5 Hoffmann-La Roche 45
7.5.1 Company Overview 45
7.5.2 Business Description 46
7.5.3 Anemia Pipeline Drugs 46
7.6 Johnson & Johnson 46
7.6.1 Company Overview 46
7.6.2 Financial Performance 46
7.6.3 Business Description 47
7.6.4 Anemia Pipeline Drugs 48
8 Anemia Market: Appendix 49
8.1 Definitions 49
8.2 Scope of Pipeline Research 49
8.3 Acronyms 49
8.4 Research Methodology 50
8.4.1 Coverage 50
8.4.2 Secondary Research 51
8.4.3 Forecasting 51
8.4.4 Primary Research 54
8.4.5 Expert Panel validation 54
8.5 Contact Us 54
8.6 Disclaimer 54
8.7 Sources 55

ABBREVIATIONS
Browse all : Pharmaceuticals Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/
Browse all : GlobalData Market
http://www.sandlerresearch.org/publishers/globaldata/
Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx

Related Reports:
Global market review of automotive roof systems - forecasts to 2017
http://www.sandlerresearch.org/Reports/17319-global-market-review-of-automotive-roof-systems-forecasts-to-20.html

Global Endoscopes Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
http://www.sandlerresearch.org/Reports/25474-global-endoscopes-pipeline-analysis-opportunity-assessment-and-m.html

Global Hospital Information Systems (HIS) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2016
http://www.sandlerresearch.org/Reports/25475-global-hospital-information-systems-his-opportunity-assessment.html

Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
http://www.sandlerresearch.org/Reports/34583-forecast-insight-antidiabetics--diabetes-market-growth-driven.html

Assessment of the Molecular Diagnostic Market for 44 NA Tests in Germany
http://www.sandlerresearch.org/Reports/10323-assessment-of-the-molecular-diagnostic-market-for-44-na-tests-in-.html

About Us:
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.

Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.

We also provide 24/7 online and offline support to our customers

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org

###

space

Other Related Press Releases